Acurx Pharmaceuticals, Inc.Financials
|
|
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin (%) | - | - | - | - | - | - | - | |
| R&D Expense | 1,834,506 | 5,403,836 | 6,043,597 | 4,754,271 | 2,030,177 | 2,202,979 | 0 | |
| SG&A Expense | 6,257,477 | 8,719,391 | 8,534,171 | 7,338,505 | 208,270 | 2,397,059 | 0 |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | ||
|---|---|---|---|---|---|---|---|---|
| Total Operating Expenses | ||||||||
| Operating Income or Loss | ||||||||
| Operating Margin (%) | ||||||||
| Income Tax Expense | ||||||||
| Net Income | ||||||||
| Net Profit Margin (%) | ||||||||
| Basic EPS | ||||||||
| Diluted EPS | ||||||||
| Basic Average Shares | ||||||||
| Diluted Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.